The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a "high-risk, high-reward" clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...
Capstan Therapeutics' CPTX2309 consists of an anti-CD19 CAR mRNA payload inside a lipid nanoparticle. (SvetaZi/Getty Images) AbbVie is making a full strength play for the in vivo CAR-T market, ...
SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid ...
June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...
U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion, expanding its pipeline with experimental treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results